As per a study published by the Indian Council of Medical Research (ICMR), 80 percent of the health care workers who have been given six or more prophylactic (to prevent the disease) doses of anti-malarial drug HCQ, have not been infected from Coronavirus.
As many organizations around the globe have contested the therapeutic (to heal the disease) utility of the anti-malarial drug, the study by ICMR establishes its prophylactic (preventive) qualities.
“The main conclusion that can be drawn after analyzing the data is that HCQ has beneficial effects in infection risk reduction from fourth dose onwards. The first loading dose of 800mg and then every week a dose of 400 mg for 4, 6 or more weeks as per your physician’s advice will help cut the risk of infection by 80% in healthcare workers who are not already sick,” says Dr Samiran Panda, director, ICMR-National AIDS Research Institute, the study co-author.
A few days ago, The Lancet, a UK based premier scientific journal, published a study which argued that giving HCQ for treatment to patients increases death risk. After the study was published, WHO, the criminally incompetent and corrupt organization, halted all trials of HCQ.
However, now hundreds of scientists have questioned the dataset used in the study published by The Lancet.
In an open letter written to editor in chief of The Lancet, Richard Horton, the scientists argued- “The paper, published May 22, included data on over tens of thousands patients hospitalized through April 14, meaning that the authors analyzed the trove of data, wrote the paper and went through the journal’s peer review of its findings in just over five weeks, much faster than usual,” as per the note published in The New York Times.
The biggest proof of fact that HCQ is not harming negatively the Covid-19 patients, and not increasing the death rate, is the mortality rate of patients in India. In India, the death rate of Covid-19 patients is lowest in the world at 1 person per million population, compared to 50 or above per million in Western countries.
In India, the hospitals are using HCQ as preventive as well as therapeutic drug, as per ICMR guidelines.
While thousands of doctors and health workers in the western countries died of the disease, as they were constantly exposed to virus; in India, the infection rate among the health workers is very low and death rate is negligible, an attribute ICMR study credits to the intake of HCQ.
It seems the Lancet study and banning of trails by WHO is a plot of American big pharmaceutical companies to promote drugs promoted by them, like Remdesivir by Gilead.
The ICMR study finding could encourage the government to give HCQ as preventive drug to people across country to built immunity against the disease. The drug has ability to inhibit infections by Coronavirus. “… Ability of this compound to inhibit the infection by SARS-CoV-2, as well as viral replication in cell cultures in a time- and dose-dependent manner made it a primary choice… These laboratory findings encouraged researchers to consider HCQ, originally used for malaria, as a repurposed agent for prophylaxis against SARS-CoV-219,” says the study.
Previously, research from China which was conducted in the very early days of Covid-19 spread, when neither the HCQ drug nor the pandemic was politicized, showed that HCQ brought down the mortality rate among the patients.
The study was conducted at Tongji Hospital in Wuhan, the initial epicenter of the pandemic, between February 1 and April 8 on 568 Covid -19 patients and was funded by China’s Ministry of Science and Technology, Nature Science Foundation and Ma Yun Foundation.
As per the study, the mortality rate among the group given HCQ was 18.8 percent compared to 43.5 percent among those who were not given the drug. “Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically-ill Covid-19 patients,” wrote the researchers.
Most of the countries around the world like Brazil, Israel, Australia, and Canada use HCQ as the first line of therapeutic defense against Covid-19. India, too, is primarily dependent on HCQ for treatment of Covid-19 patients and a high recovery rate and low mortality rate in the country shows that, so far, HCQ is the most effective drug against disease.
From these studies, it seems that famed Western journals have become a pawn in the hand of big pharmaceutical companies. And they are discriminating against the drug that is primarily produced in India, is cheaper, and more effective.